Uterine leiomyomas (ULM) are histologically and molecularly heterogeneous and clinically they grow at vastly different rates. Several driver gene mutations have been identified in ULM, including MED12 mutations, HMGA2 overexpression, and biallelic FH inactivation. ULM with different driver mutant genes may use different molecular pathways, but currently no clear correlation between gene mutations and growth related pathways has been established. To better define this relationship, we collected ULM with MED12 (n = 25), HMGA2 (n = 15), and FH (n = 27) mutations and examined the sex steroid hormone, cell cycle, and AKT pathway genes by immunohistochemistry. While ER and PR were highly expressed in all types of ULM, FH ULM showed lower ER expression and higher PR expression. HMGA2 tumors had significantly higher levels of AKT signaling and mitogenic activity than other ULM types. HMGA2 activated AKT signaling through upregulation of IGF2BP2. Silencing HMGA2 in ULM cells resulted in downregulation of AKT and upregulation of p16 and p21, which eventually led to cell senescence. HMGA2 overexpression in ULM is not only related to tumor development but also plays a role in controlling cellular proliferation through the AKT pathway.
| INTRODUCTION
Uterine leiomyomas (ULM) are an important public health problem due to the high incidence among women and the high rate of surgical intervention with myomectomy or hysterectomy. 1 Up to 70% of women develop ULM during their lifetime 2 and current medical therapies show no significant long term benefits, but carry significant side effects. ULM are a histologically and molecularly heterogeneous group of tumors and grow at vastly different rates. 3 Yet the pathogenesis of ULM leading to the varied histology and growth behavior is largely unknown. In recent studies, several driver gene mutations have been identified in ULM, including MED12 mutations in exon 2 in 60-70% of cases, HMGA2 overexpression in 10-15% of cases, and biallelic FH inactivation in rare cases. 4, 5 Global gene expression analysis indicates that different mutant genes in ULM may target different molecular pathways 5 and each mutation type may theoretically determine growth behavior, but these theories have not yet been proven. Notably, a uterus with multiple ULM can show somatic mutations of different genes and each given tumor only acquires a single driver gene mutation, since the mutations are mutually exclusive. 4, 6, 7 Thus, ULM consist of a group of genetically heterogeneous tumors with similar histogenesis.
Such genetic differences in ULM due to different driver gene mutations may determine their histological and molecular heterogeneity and further influence tumor growth rates. However, histology and molecular pathway correlation with these driver gene mutations has not been established or characterized. HMGA2 overexpression in ULM is caused by a translocation between 12q and 14q 8 and the early studies showed that ULM with HMGA2 overexpression tend to be larger and grow faster than those without HMGA2 alterations. 5, 9, 10 HMGA2 ULM cannot be differentiated histologically from other ULM, but it is common in a variant of ULM defined as intravascular leiomyomatosis. 11 Unfortunately, while many oncogenic functions of HMGA2 in malignant tumors are characterized, 12 little is known about how HMGA2 causes and promotes ULM development and growth.
MED12 mutations are the most common somatic mutations in ULM.
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MED12 is essential for activating CDK8 and modulates mediatorpolymerase II interactions for transcription initiation. 14 Growth of MED12 ULM may require and recruitment of prominent myomaassociated fibroblasts. 15 FH ULM exhibit characteristic histologic features in leiomyomas of bizarre nuclei. 16, 17 Further investigation of the molecular and histological difference in ULM with different driver gene mutations may assist in understanding biological and medical significance and aid in clinical management.
Because sex steroid hormones, cell cycle and AKT signaling are prevalent pathways for ULM growth, we aimed in this study to examine these common functional pathways in ULM with different driver mutations. We collected ULM with MED12, HMGA2, and FH mutations and examined the selected markers by immunohistochemistry.
The functional correlation between AKT and HMGA2 was further analyzed in primary cultures of ULM.
| MATERIALS AND METHODS

| Case Selection
Human myometrial and leiomyoma tissues were collected from pre- 
| SDS-PAGE and Western Blotting
Protein lysates were extracted from myometrial and leiomyoma cells using RIPA lysis and extraction buffer with protease and phosphatase inhibitors (Thermo Fisher Scientific). The protein concentration was determined using BCA Protein Assay kit (Thermo Fisher Scientific).
Equal amounts of proteins were subjected to SDS-PAGE and subsequently transferred to polyvinylidene difluoride (PVDF) membranes.
Immunoblotting was performed using the following primary anti- 
| HMGA2 siRNA Transient Transfection
Cells were grown to 60-80% confluency at the day of transfection, and then were either transfected with control siRNA (Stealth RNAi negative control duplexes, ThermoFisher Scientific) or HMGA2 siRNA (Stealth siRNA, HSS111974, ThermoFisher Scientific) according to the manufacturer's instruction using Lipofectamine RNAiMAX (ThermoFisher Scientific), as described previously in detail. 12 
| Tissue Microarrays
Formalin-fixed paraffin-embedded (FFPE) tissue blocks from myometrium and ULM were selected for each case and 2 mm 2 tissue cores were taken to create tissue microarrays (TMAs). The TMAs were sectioned at 4 μm. The first and last slides were stained with hematoxylin and eosin (H&E) for quality assurance to confirm the correct tumor types and the presence of viable tumor tissue.
| Immunohistochemistry
The analytical markers for immunohistochemical (IHC) analysis included steroid hormone receptors (ER and PR), cell cycle marker (p16), and cell proliferative marker (Ki-67), and AKT pathway markers (pAKT, pS6, IGF2BP2). The driver gene markers of FH, HMGA2 and MED12 were also included. All immunohistochemical staining procedures were performed on a Ventana Nexus automated system as described previously. 6 All information regarding selected antibodies is summarized in Supporting Information Table 1 . The percent and intensity of each staining were evaluated by two pathologists. The intensity was scored as negative (0), weak (1+), moderate (2+), or strong (3+) and the percentage of positive tumor cells was scored from 0% to 100%. The results were then semi-quantitatively analyzed. 
| Statistical Analysis
| Sex steroid hormone expression in different types of ULM
The relative expression of estrogen receptor (ER) and progesterone receptor (PR) were scored semi-quantitatively using percentage and intensity of staining. In all myometrial controls, ER and PR expression was high with a median score of 70% (95% of CI in 58-74%; Table 2 ).
Overall, ULM also showed high levels of ER and PR expression with a range of 45-80% staining. No significant difference between myometrial controls and ULM was noted. When ER and PR expression was reviewed based on different gene mutations, FH ULM had significantly lower ER expression (45%) and bordering higher PR expression (84%) than both the other ULM subtypes and the myometrial controls (P = 0.0049, P = 0.058, respectively, Table 2 , Figure 2 ). In fact, over 25% of FH ULM showed no ER expression (Figure 2A ). In contrast,
HMGA2 and MED12 ULM showed no significant difference in ER or PR expression and no difference when compared with myometrial controls (P > 0.05). Similar trends were noted when comparing the staining intensity of ER and PR among the three variants (Table 2 ).
These findings suggest that two of the molecular ULM subtypes maintain high levels of ER and PR expression. In contrast, the inverse association of ER and PR expression in FH ULM is noted with underlying mechanisms yet to be characterized.
| Expression analysis of p16 and Ki-67
P16 is a major cell cycle regulator. In malignant tumors including leiomyosarcoma, diffuse p16 expression reflects loss of function due to an RB defect in the negative feedback loop. 18 In normal or benign tumors like nevi and ULM, p16 expression serves as a cell cycle inhibitor driving cells into senescence. 19, 20 To determine whether different driver gene mutations influenced tumor growth and arrest through p16, IHC staining for p16 was done in ULM. Overall ULM showed very low levels of p16 expression ranging from 1 to 5% p16 immunoreactivity. HMGA2 ULM had almost undetectable p16 expression (0-3%) in comparison to MED12 ULM (4.5-12.3%) and FH ULM (4.9-17.1%), which was statistically significant (P < 0.05%, Table 2 , Figure 2C ). This finding also correlated with a much higher proliferation index (Ki67) ranging from 5.6-14% in HMGA2 ULM in Figure 2D , Table 2 ). These findings suggest that HMGA2 promotes leiomyoma growth through its negative regulation of p16 expression.
| Expression analysis of AKT pathway
AKT has been found to be activated in ULM and promotes fibroid growth and survival within an unfavorable hypoxic microenvironment. 21 AKT activation in ULM is not fully understood but we have demonstrated its association with the ROS pathway. 22 Here, we examined the levels of activated AKT and its direct downstream target, pS6, in ULM with the three different gene mutations. HMGA2
ULM showed strong, diffuse immunoreactivity for pAKT and pS6. In contrast, weak to moderate immunoreactivity for pAKT and pS6 was present in MED12 and FH ULM as well as in the myometrial controls ( Figure 3 , Table 2 ).
Previous gene profiling studies have shown that ULM with
HMGA2 overexpression have increased IGF2BP2 expression. 5 To test whether IGF2BP2 is a major upstream mediator for IGF2, we examined IGF2BP2 levels by immunohistochemistry. As illustrated in Figure 3B ,C, almost all HMGA2 ULM showed strong and diffuse immunoreactivity for IGF2BP2. In contrast, the other two subtypes and the myometrial controls showed low levels of IGF2BP2 (P < 0.001). These findings suggest that an important interaction of IGF2BP2 and AKT occur in specifically HMGA2 ULM.
| Molecular analysis of HMGA2-mediated AKT signaling in ULM
The immunohistochemistry results suggest that ULM with HMGA2 overexpression have significantly higher proliferation index, higher AKT activity, and lower p16 expression than the other two genetic subtypes. Thus, primary leiomyoma cells were used to evaluate the role of HMGA2 in modulating AKT, p16 and p21. ULM with MED12
mutations (low HMGA2 levels) were used to overexpress HMGA2 using lentiviral transduction using two MOIs, low (0.5) and HMGA2 levels ( Figure 4A ). Next, using HMGA2 ULM, HMGA2 was silenced using siRNA. With decreased HMGA2 levels, decreased pAKT levels were observed ( Figure 4B-D) . These data demonstrate the ability of HMGA2 to regulate AKT activity. To evaluate whether AKT regulates HMGA2 levels in ULM, AKT was blocked by the AKT inhibitor MK2206 and no significant change of HMGA2 expression was noted ( Figure 4E ). These data support that HMGA2 upregulates AKT and not the reverse. HMGA2, ULM cells at P0 had higher expression of HMGA2. In contrast, ULM at P1 and P2 exhibited decreased expression of HMGA2
suggesting that HMGA2 downregulation is correlated with replicative senescence. To confirm that downregulation of HMGA2 in primary culture of fibroid cells was the major driving force for cellular senescence, P0 cells were transfected with HMGA2 siRNA and cellular senescence was examined by a β-Gal stain. As shown in Figure 5B , cells treated with HMGA2 siRNA had significantly increased levels of β-Gal staining, indicative of cellular senescence than the cells treated with control siRNA (53% vs. 38%, P < 0.05). Similar effects were observed when we used ELISA to measure β-Gal activity ( Figure 5C ).
In addition, we observed in Figure 5D that silencing of HMGA2 in ULM led to upregulation of both p16 and p21. Our findings suggest that the aggressive behavior of HMGA2 ULM is due to increased HMGA2 mutations are the second most common driver mutations in ULM, accounting for 10-15% of the cases. 6 HMGA2 ULM tend to be larger and faster-growing tumors in comparison to MED12 and FH (Table 1) . 5, 9, 10 HMGA2 is a transcriptional regulator and is highly associated with many functions, such as tumorigenesis, stem cell renewal, cell proliferation and cellular senescence. The function of HMGA2 heavily relies on the cell type. For example, in ovarian and other cancer cells, HMGA2 is an oncogene and promotes aggressive tumor growth through its multiple oncogenic properties. 23 In normal or benign tumor cells, it can promote cell proliferation and sensitizes to stress and oncogene-induced senescence. 24 HMGA2 ULM are a subset of tumors which do not share the same major pathways as the other genetic subtypes and previous studies have demonstrated that repression of HMGA2 by let-7 and other mechanisms resulted in decreased tumor growth. 25 Additionally, HMGA2 ULM are larger and have higher rate of cell proliferation, supporting HMGA2 as a mitogenic factor. Transgenic mouse models indicated that HMGA2 can sufficiently repress p16 expression for stem cell self-renewal. 26 Because AKT pathway is one of the major pathways that regulates ULM growth, 22, [27] [28] [29] HMGA2 regulation of the AKT pathway is a significant discovery for ULM.
It has been shown that decreased HMGA2 expression in acute myeloid leukemia cells inhibited cell proliferation through a decrease in the protein expression of pAKT and p-mTOR. 30 HMGA2 may also directly regulate IGF2BP2 to influence IGF2 bioavailability in other cell types. 5, 31 IGF2 is one of the major growth factors highly overexpressed in ULM. 32 We previously reported that IGF2 is overexpressed in ULM at the transcriptional level without changing IGF2 imprinting status in ULM. 33 Given that HMGA2 may enhance IGF2 through IGF2BP2, we postulated that HMGA2 overexpression can activate the AKT pathway in ULM and we indeed found that ULM with HMGA2 overexpression showed a significant positive correlation with IGF2BP2, pAKT and pS6 overexpression (Figure 3 ). This finding was further validated by using in vitro primary leiomyoma cells (Figure 4 ).
The results of our study provide further evidence that ULM with HMGA2 overexpression can enhance AKT activity for tumor growth and survival.
In addition to promoting cell proliferation, HMGA2 is also a major player in cellular senescence either under oncogenic 24 or environmental 29 stress. Several recent studies have shown that HMGA2 regulates cell cycle genes. Silencing of HMGA2 leads to the induction of cell cycle inhibitors, including cyclin D1, cyclin B1, and cyclin E expression and increases the number of cells in G0/G1 phase. [34] [35] [36] Interestingly, in our current study, we found that HMGA2 expression was inversely proportional to p16 expression ( Figure 2 ). When HMGA2 was silenced in leiomyoma cells, it also resulted in the upregulation of p16 and p21 ( Figure 5 ), leading to reduced tumor growth and increased cellular senescence ( Figure 5 ). Based on this study, HMGA2-mediated AKT signaling and its regulation to cell proliferation and senescence in ULM is summarized in Figure 6 .
Overall, we have shown that ULM with different driver gene mutations harbor different molecular pathways in regulating cell growth in ULM. These differences are reflected by their different growth rates and responses to environmental stress. Thus, HMGA2 ULM are a group of tumors that could be treated differently from other ULM. In contrast, growth of MED12 ULM may rely on tumor associated fibroblasts. 15 Therefore, with a better characterization of specific targets in ULM with different driver gene mutations, cell growth could be halted and cellular senescence could be induced in a more specific way. Moreover, gene mutation analysis in myomectomy specimen may help to predict the potential tumor growth and guide further clinical management when HMGA2 overexpression is detected.
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